Aspire Private Capital LLC Reduces Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Aspire Private Capital LLC lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 69.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,368 shares of the medical research company’s stock after selling 3,128 shares during the quarter. Aspire Private Capital LLC’s holdings in IQVIA were worth $269,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. Capital Performance Advisors LLP acquired a new position in IQVIA in the third quarter valued at $27,000. Park Place Capital Corp acquired a new position in IQVIA during the third quarter worth approximately $28,000. Avior Wealth Management LLC lifted its stake in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the last quarter. Assetmark Inc. grew its position in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after acquiring an additional 196 shares during the last quarter. Finally, UMB Bank n.a. raised its position in IQVIA by 74.4% in the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 99 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Trading Up 4.0 %

Shares of IQV stock opened at $205.23 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The business has a fifty day simple moving average of $199.69 and a 200-day simple moving average of $221.32. The stock has a market cap of $37.25 billion, a P/E ratio of 26.93, a P/E/G ratio of 2.01 and a beta of 1.48.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of research reports. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Barclays decreased their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. BTIG Research dropped their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Evercore ISI decreased their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $255.71.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.